Friday, 16 October 2026European Markets

AKER HORIZONS Stock Went Down By Over 27% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of AKER HORIZONS (Oslo Børs Benchmark Index_GI: AKH.OL) dropped by a staggering 27.52% in 21 sessions from kr8.32 to kr6.03 at 11:23 EST on Wednesday, after five successive sessions in a row of losses. Oslo Børs Benchmark Index_GI is rising 0.42% to kr1,210.74, after three successive sessions in a row of gains.

AKER HORIZONS's last close was kr5.99, 72.45% below its 52-week high of kr21.74.

About AKER HORIZONS

Aker Horizons ASA, through its subsidiaries, develops and invests in a portfolio of companies in the renewable energy and green technology comprising private and public companies worldwide. It sources, develops, structures, builds, and operates wind and solar power assets; and develops, builds, owns, and operates clean hydrogen production at industrial scale. The company also provides products, technology, and solutions within the field of carbon capture, utilization, and storage. In addition, it offers products and services to the hydropower industry; designs and delivers superconducting systems; and produces silicon materials. The company was incorporated in 2020 and is headquartered in Lysaker, Norway. Aker Horizons ASA is a subsidiary of Aker Capital AS.

Earnings Per Share

As for profitability, AKER HORIZONS has a trailing twelve months EPS of kr-3.56.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -44.47%.

Yearly Top and Bottom Value

AKER HORIZONS's stock is valued at kr6.03 at 11:23 EST, way under its 52-week low of kr6.93.

Revenue Growth

Year-on-year quarterly revenue growth grew by 59.2%, now sitting on 2.37B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, AKER HORIZONS's stock is considered to be overbought (>=80).

Moving Average

AKER HORIZONS's worth is way under its 50-day moving average of kr8.74 and way under its 200-day moving average of kr12.90.

More news about AKER HORIZONS (AKH.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com